Progress in adjuvant therapy decision-making after endoscopic resection of early esophageal cancer

中华放射肿瘤学杂志 Pub Date : 2019-11-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2019.11.015

F. Lingling, M. Yu, H. Zhouguang

{"title":"Progress in adjuvant therapy decision-making after endoscopic resection of early esophageal cancer","authors":"F. Lingling, M. Yu, H. Zhouguang","doi":"10.3760/CMA.J.ISSN.1004-4221.2019.11.015","DOIUrl":null,"url":null,"abstract":"Both endoscopic resection and surgery are the common treatment modes for early esophageal cancer. Compared with radical surgery, endoscopic resection has the advantages of less trauma, quicker recovery, lower cost, less complications, the preservation of the normal anatomy, the physiological function of the esophagus, and higher postoperative quality of life. For patients with a high risk of lymph node metastasis, endoscopic resection alone can lead to inadequate treatment, which need adjuvant therapies. Currently, the common adjuvant therapies consist of adjuvant radiochemotherapy and adjuvant radiochemotherapy combined with surgery. How to combine endoscopic resection with adjuvant therapy to bring maximal benefits to patients has become the hot topic in the field of clinical researches. In this article, the current research status, progress and challenges in the combination of endoscopic resection and adjuvant therapy for the treatment of high-risk patients were reviewed. \n \nKey words: \nEsophageal neoplasm/endoscopic resection; Esophageal neoplasm/surgery; Esophageal neoplasms/chemoradiotherapy; Progress","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"28 1","pages":"867-871"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2019.11.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Both endoscopic resection and surgery are the common treatment modes for early esophageal cancer. Compared with radical surgery, endoscopic resection has the advantages of less trauma, quicker recovery, lower cost, less complications, the preservation of the normal anatomy, the physiological function of the esophagus, and higher postoperative quality of life. For patients with a high risk of lymph node metastasis, endoscopic resection alone can lead to inadequate treatment, which need adjuvant therapies. Currently, the common adjuvant therapies consist of adjuvant radiochemotherapy and adjuvant radiochemotherapy combined with surgery. How to combine endoscopic resection with adjuvant therapy to bring maximal benefits to patients has become the hot topic in the field of clinical researches. In this article, the current research status, progress and challenges in the combination of endoscopic resection and adjuvant therapy for the treatment of high-risk patients were reviewed. Key words: Esophageal neoplasm/endoscopic resection; Esophageal neoplasm/surgery; Esophageal neoplasms/chemoradiotherapy; Progress

查看原文本刊更多论文

内镜下早期食管癌切除术后辅助治疗决策的研究进展

内镜切除和手术是早期食管癌常见的治疗方式。与根治性手术相比，内镜切除具有创伤小、恢复快、费用低、并发症少、保留正常解剖结构、食道生理功能、术后生活质量高等优点。对于淋巴结转移的高危患者，单纯内镜切除可能导致治疗不足，需要辅助治疗。目前常见的辅助治疗包括辅助放化疗和辅助放化疗联合手术。如何将内镜切除与辅助治疗相结合，使患者获得最大的利益，已成为临床研究领域的热点。本文就内镜切除与辅助治疗联合治疗高危患者的研究现状、进展及面临的挑战进行综述。关键词:食管肿瘤/内镜切除;食管肿瘤/手术;食管肿瘤/化疗;进步

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.